According to the latest report by IMARC Group, titled “Veterinary Medicine Market Report by Product (Drugs, Vaccines, Medicated Feed Additives), Animal Type (Production, Companion), Route of Administration (Oral, Parenteral, Topical), Distribution Channel (Veterinary Hospitals and Clinics, Point-of-Care Testing/In-house Testing, and Others), and Region 2024-2032," the global veterinary medicine market reached a value of US$ 35.4 Billion in 2023. Veterinary medicine is a branch of science that deals with maintaining health and preventing, alleviating, and curing diseases that affect domestic and wild animals. It includes various drugs, medicated feed additives and vaccines that are used to build immunity in animals against various infectious diseases, such as equine influenza (EIV) and parainfluenza 3-respiratory syncytial. Veterinary medicines aid in maintaining health, inhibiting the transmission of zoonotic diseases from animal species to humans, and providing advanced medical, dental, and surgical care.
Global Veterinary Medicine Market Trends:
The increasing prevalence of infectious diseases among pets and wild animals across the globe represents one of the key factors creating a positive outlook for the market. Veterinary medicine is widely used to treat and manage various zoonotic diseases, such as echinococcosis, leptospirosis, toxoplasmosis, cysticercosis, Nipah, rabies, plague, trypanosomiasis, and kyasanur forest disease (KFD). Furthermore, the rising consumption of meat and dairy products and the expanding animal husbandry activities have facilitated the demand for veterinary medicines to meet the concerns of food safety, which, in turn, is acting as another growth-inducing factor. Additionally, growing animal health awareness amongst pet owners and the rising demand for efficient pet care solutions are positively impacting the market growth.
Apart from this, the introduction of cloud-based wearable devices that assist in monitoring animal health and keep track of body temperature, heart rate, respiration rate, and pH levels are providing an impetus to the market growth. Moreover, the easy availability of advanced regenerative medicines, diagnostic imaging, laser diagnostics, novel therapies, and specialized surgeries across numerous vet hospitals and clinics is positively influencing the market growth. Other factors, including the introduction of safe and effective vaccines to prevent pet diseases, rising expenditure capacities of consumers, and increasing domestication of animals, are anticipated to drive the market toward growth. On account of the aforementioned factors, the market is expected to reach a value of US$ 59.1 Billion by 2032, exhibiting a CAGR of 5.7% during 2024-2032.
Market Summary:
- On the basis of the product, the market has been divided into drugs (anti-infective, anti-inflammatory, and parasiticide), vaccines (inactivated, attenuated, and recombinant vaccines), and medicated feed additives (amino acids and antibiotics).
- Based on the animal type, the market has been bifurcated into production and companion.
- Based on the route of administration, the market has been categorized into oral, parenteral, and topical.
- On the basis of the distribution channel, the market has been divided into veterinary hospitals and clinics, point-of-care testing/in-house testing, and others.
- Based on the region, the market has been categorized into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and Others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and Others) Latin America (Brazil, Mexico and Others), Middle East and Africa.
- The competitive landscape of the industry has also been examined in the report. Some of the key players include Archer-Daniels-Midland Company, Boehringer Ingelheim GmbH, Cargill Incorporated, Ceva Santé Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health Incorporated, Evonik Industries AG, Merck & Co. Inc., Neogen Corporation, Vetoquinol S.A., Virbac and Zoetis Inc.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
US$ Billion |
Segment Coverage |
Product, Animal Type, Route of Administration, Distribution Channel, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Archer-Daniels-Midland Company, Boehringer Ingelheim GmbH, Cargill Incorporated, Ceva Santé Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health Incorporated, Evonik Industries AG, Merck & Co. Inc., Neogen Corporation, Vetoquinol S.A., Virbac and Zoetis Inc. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Website: https://www.imarcgroup.com/
Email: sales@imarcgroup.com
Americas: +1-631-791-1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800